Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. It targets cytokines IL-12 and IL-23, which are involved in immune-mediated inflammatory disorders.
The IDKmonitor Ustekinumab TOTAL Anti-drug Antibody ELISA measures free and bound antibodies against ustekinumab (e.g. STELARA®). This drug-tolerant assay enables the reliable determination of anti-drug antibodies even in the presence of ustekinumab. This means it is ideal for therapy monitoring when a measurable ustekinumab concentration is expected, for example, shortly after the last infusion. In combination with the drug level determination, the IDKmonitor Ustekinumab TOTAL Anti-drug Antibody ELISA supports the monitoring and optimisation of therapy.
